Genmab , Yalelaan 60, 3584CM, Utrecht, The Netherlands.
Thermo Fisher Scientific GmbH , Im Steingrund 4-6, 63303, Dreieich, Germany.
Anal Chem. 2017 Oct 17;89(20):10873-10882. doi: 10.1021/acs.analchem.7b02543. Epub 2017 Oct 2.
Bispecific antibodies (bsAbs) are one of the most versatile and promising pharmaceutical innovations for countering heterogeneous and refractory disease by virtue of their ability to bind two distinct antigens. One critical quality attribute of bsAb formation requiring investigation is the potential randomization of cognate heavy (H) chain/light (L) chain pairing, which could occur to a varying extent dependent on bsAb format and the production platform. To assess the content of such HL-chain swapped reaction products with high sensitivity, we developed cysteine-stable isotope labeling using amino acids in cell culture (SILAC), a method that facilitates the detailed characterization of disulfide-bridged peptides by mass spectrometry. For this analysis, an antibody was metabolically labeled with C,N-cysteine and incorporated into a comprehensive panel of distinct bispecific molecules by controlled Fab-arm exchange (DuoBody technology). This technology is a postproduction method for the generation of bispecific therapeutic IgGs of which several have progressed into the clinic. Herein, two parental antibodies, each containing a single heavy chain domain mutation, are mixed and subjected to controlled reducing conditions during which they exchange heavy-light (HL) chain pairs to form bsAbs. Subsequently, reductant is removed and all disulfide bridges are reoxidized to reform covalent inter- and intrachain bonds. We conducted a multilevel (Top-Middle-Bottom-Up) approach focusing on the characterization of both "left-arm" and "right-arm" HL interchain disulfide peptides and observed that native HL pairing was preserved in the whole panel of bsAbs produced by controlled Fab-arm exchange.
双特异性抗体 (bsAb) 是最通用和最有前途的药物创新之一,通过结合两种不同的抗原,能够对抗异质和难治性疾病。bsAb 形成的一个关键质量属性是需要研究的潜在同源重 (H) 链/轻 (L) 链配对的随机化,这可能会因 bsAb 格式和生产平台的不同而在不同程度上发生。为了以高灵敏度评估这种 HL 链交换反应产物的含量,我们开发了使用细胞培养物中的氨基酸进行半胱氨酸稳定同位素标记 (SILAC),这是一种通过质谱法详细表征二硫键桥接肽的方法。为此分析,一种抗体通过 C,N-半胱氨酸进行代谢标记,并通过受控 Fab 臂交换 (DuoBody 技术) 将其掺入到独特的双特异性分子的综合面板中。该技术是产生双特异性治疗性 IgG 的一种后生产方法,其中几种已进入临床阶段。在此,两种亲本抗体,每种都包含单个重链结构域突变,混合在一起,并在受控的还原条件下进行处理,在此过程中它们交换重轻 (HL) 链对以形成 bsAb。然后,去除还原剂并重新氧化所有二硫键以重新形成共价的链间和链内键。我们进行了多层次(从上到下、从中间到下)的方法,重点是对“左臂”和“右臂”HL 间链二硫键肽的特征进行分析,并观察到在通过受控 Fab 臂交换产生的整个 bsAb 面板中保持了天然的 HL 配对。